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BY-NC-ND license (http://creativecomBackground/purpose: Transforming growth factor (TGF)-b is a key regulator in the pathogen-
esis of oral submucous fibrosis (OSF). Early growth response (Egr)-1 is essential for fibrotic re-
sponses to TGF-b. Because TGF-b signaling is cell-type- and context-dependent, we
investigated the signaling involved in TGF-b-induced Egr-1 in primary human buccal mucosal
fibroblasts (BMFs).
Methods: TGF-b-induced Egr-1 and its signaling were assessed by western blotting in BMFs. Egr-
1 small interfering RNA was used to define the role of Egr-1 on TGF-b-induced mRNAs of the a1-
and a2-chains of type I collagen (COL1A1 and COL1A2) and acid-soluble collagen production
(via Sircol collagen assay). The effects of epigallocatechin-3-gallate (EGCG) on TGF-b-induced
Egr-1 protein and acid-soluble collagen were also evaluated.
Results: TGF-b1 stimulated Egr-1 production in BMFs. Pretreatment with PD98059, SP600125,
SB431542, and SIS3, but not SB203580, significantly reduced TGF-b1-induced Egr-1 protein
expression. Genetic targeting of Egr-1 completely inhibited TGF-b1-induced type I collagen
mRNAs and collagen protein expression. EGCG fully inhibited TGF-b1-induced Egr-1 and TGF-
b1-stimulated production of acid-soluble collagens.
Conclusion: We conclude that activin receptor-like kinase (ALK)5, Smad3, extracellular signal-
regulated kinase, and c-Jun N-terminal kinase are involved in the TGF-b1-induced Egr-1 pro-
tein production in BMFs. Egr-1 mediates TGF-b1-induced COL1A1 and COL1A2 mRNA expression
and acid-soluble collagen production in BMFs. EGCG can block TGF-b1-induced collagenave no conflicts of interest relevant to this article.
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108 Y.-P. Hsieh et al.production by attenuating Egr-1 expression in BMFs. Egr-1 is a key mediator in TGF-b1-induced
pathogenesis of OSF. EGCG may be useful in the prevention or treatment of OSF.
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Oral submucous fibrosis (OSF) is a precancerous condition of
the oral cavity. In the advanced stage of OSF, type I
collagen is the major extracellular matrix constituent in the
lamina propria and submucosal layer of the oral cavity.1
Areca nut (AN; Areca catechu) chewing is the most impor-
tant etiological factor for OSF. The major AN alkaloid,
arecoline, causes imbalance between collagen degradation
and synthesis.2 Exposure to AN and stimulation of the
transforming growth factor (TGF)-b pathway are respon-
sible for overproduction of collagen and decreased degra-
dation of collagen in OSF.3 Immunohistochemistry has
shown intense TGF-b staining of epithelium, fibroblast,
macrophages, and inflammatory cells in early OSF.4 Areco-
line upregulates expression of avb6 integrin in oral kerati-
nocytes; the avb6-dependent TGF-b1 activation further
induces myofibroblast transdifferentiation and contributes
to the pathogenesis of OSF.5 At present, no known treat-
ment completely reverses the process of OSF. Although
anti-TGF-b therapy has shown significant antifibrotic ef-
fects in animal models, systemically administered and
repeated doses of anti-TGF-b1 drug therapy in systemic
sclerosis resulted in significant morbidity and mortality in a
multicenter, randomized, placebo-controlled clinical trial.6
TGF-b regulates important physiological processes,
including tumor suppression7 and immunosuppression.8
Inhibiting TGF-b activity causes spontaneous autoimmu-
nity and epithelial hyperplasia, or interferes with wound
healing.9 Thus, therapeutic targets other than TGF-b need
to be evaluated.
Early growth response (Egr)-1 is an immediate early gene
located on human chromosome 5q31, encoding an 80-kDa
zinc-finger transcription factor that binds to guanine-cyto-
sine (GC)-rich regulatory DNA elements in the promoter
region of many target genes.10 It plays important roles in
cellular growth, differentiation, and activation of cell
death pathways. It is normally low or undetectable, how-
ever, it is induced rapidly and transiently by a wide range of
environmental stimuli, including TGF-b.10,11 Sustained
expression of Egr-1 contributes to pathological responses.
Increased Egr-1 is detected in lesional human fibrotic tis-
sues from atherosclerotic plaques, idiopathic pulmonary
fibrosis, and lung and skin of scleroderma.11 Our recent
study has demonstrated elevated Egr-1 staining in OSF
specimens.12 We have also shown that arecoline stimulates
Egr-1 in normal human buccal mucosal fibroblasts (BMFs),
implying a role of Egr-1 in the pathogenesis of OSF.12
Egr-1 is an important mediator of TGF-b-induced re-
sponses.10 TGF-b induces rapid and transient accumulation
of Egr-1 mRNA and protein in normal fibroblasts.13 Egr-1
subsequently stimulates collagen synthesis, myofibroblastdifferentiation, and other fibrotic responses, including the
secretion of fibrogenic growth factors and cytokines,
leading to a positive feedback loop to contribute to the
development and persistence of fibrosis.11 Type I collagen,
the principal matrix protein deposited in OSF, is a hetero-
trimeric molecule composed of two a1-chains and one a2-
chain. The a1-chain and a2-chain of type I collagen
(COL1A1 and COL1A2) promoters contain binding sites for
Egr-1.13,14 Forced expression of Egr-1 is sufficient by itself
to upregulate COL1A2 promoter activity and further
enhance the synthesis of type I collagen.13 Egr-1-null mu-
rine embryonic fibroblasts show attenuated synthesis of
TGF-b-induced type I procollagen.13 In explanted Egr-1-null
murine skin fibroblasts, TGF-b stimulation of collagen syn-
thesis, cell migration, and myofibroblast trans-
differentiation are all significantly impaired.15 Therefore,
Bhattacharyya et al11 suggested Egr-1 as the new conductor
in orchestrating fibrotic responses.
Considering the broad range of the biological roles of
Egr-1, it is interesting that Egr-1-deficient mice are viable
yet without apparent phenotype except for female infer-
tility, reduced body size, impaired liver regeneration, or
some altered tissue remodeling.11 Therefore, in the context
of treating fibrosis, Egr-1 should be better than TGF-b as a
therapeutic target. Because Egr-1 is crucial for TGF-b-
dependent fibrotic responses and because TGF-b signaling
is cell-type- and context-dependent,16 we investigated the
signaling pathways of TGF-b-induced Egr-1 expression in
normal human BMFs and the effects of blocking Egr-1 on the
expression of TGF-b-induced COL1A1 and COL1A2 mRNAs
and the production of TGF-b-induced collagen synthesis in
BMFs. We further explored whether green tea polyphenol,
epigallocatechin-3-gallate (EGCG), affected TGF-b-induced
Egr-1 and collagen synthesis in BMFs.Methods
Cell culture
Under the approval of the Research Ethic Committee of Na-
tional Taiwan University Hospital (approval number:
201305062RINC), three primary BMFs cultures were estab-
lished with informed consent obtained from patients as
described previously.12 Cells were plated on 60-mm Petri
dishes at a density of 2 105 cells, followed by 24 hours serum
deprivation before treatment with TGF-b1 (R&D Systems,
Minneapolis, MN, USA). To study the potential signaling
transduction pathways, BMFs were pretreated with 10mM
extracellular signal-regulated kinase (ERK) inhibitor PD98059,
10mM kinase (JNK) inhibitor SP600125, 10mM p38 mitogen-
activated protein kinase (MAPK) inhibitor SB203580, 10mM
Figure 1 TGF-b1 stimulated Egr-1 protein expression in
normal human BMFs. BMFs were treated with 2 ng/mL TGF-b1.
Egr-1 protein levels were measured by western blot analysis.
Experiments were repeated three times with BMF Strain 1 for
statistical analyses and were verified once with each of the
other two strains. All of the experimental results were similar.
A representative result is shown. Results were further quanti-
fied by densitometric analysis, normalized by the level of b-
actin, and expressed as the fold-change relative to the un-
treated controls. * p < 0.05 compared with the control.
BMF Z buccal mucosal fibroblast; Egr Z early growth
response; TGF Z transforming growth factor.
EGCG suppress Egr-1-mediated TGFb-induced collagen 109activin receptor-like kinase (ALK)5 inhibitor SB431542, or10mM
Smad3 phosphorylation inhibitor SIS3 (CalBiochem, San Diego,
CA, USA), for 1 hour before exposure to 2 ng/mL TGF-b1 for
2 hours. All tissue culture biological agents were from Invi-
trogen (Carlsbad, CA, USA).
Western blot analysis
The methods used were similar to those reported in our
previous study.12 Cells were harvested, subjected to lysis,
separated, and immunoblotted. The antibodies and di-
lutions used included: Egr-1 (1:500; Cat. No. sc-189; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), b-actin (1:2000;
Cat. No. sc-47778; Santa Cruz Biotechnology), goat anti-
rabbit secondary antibody (1:10000; Cat. No. ab6721;
Abcam, Cambridge, MA, USA), and rabbit antimouse sec-
ondary antibody (1:10000; Cat. No. ab6728; Abcam). The
immunoreactive signals were visualized using Western
Lighting Chemiluminescence Reagent (PerkinElmer, Well-
esley, MA, USA) and the Fuji LAS-4000 lumino image
analyzer (Fuji Photo Film Co., Tokyo, Japan).
Quantitative real-time polymerase chain reaction
The methods used were similar to those reported in our
previous study.12 TaqMan probes for COL1A1 (ID:
Hs00164004_m1), COL1A2 (ID: Hs00164099_m1), and glyc-
eraldehyde 3-phosphate dehydrogenase (GADPH; ID:
Hs99999905_m1) were used. GADPH was used as a refer-
ence gene.
Sircol collagen assay
BMFs (105 cells) were cultured in six-well culture plates and
grown to near confluence. After overnight serum starva-
tion, cells were treated with 60nM Egr-1 small interfering
RNA (siRNA) or (2.5mM, 5mM, or 10mM) EGCG for 48 hours
followed by 2 ng/mL TGF-b1 treatment. Total acid-soluble
collagen in BMFs and cell culture supernatants were
collected and determined using a Sircol Collagen Assay kit
as recommended by the manufacturer (Biocolor Ltd., Car-
rickfergus, UK).
RNA interference
Endogenous Egr-1 and Smad2/3 expression in BMFs was
inhibited with Egr-1 and Smad2/3 siRNA (Santa Cruz
Biotechnology) using siRNA Transfection Reagent (Santa
Cruz Biotechnology). BMFs were cultured for an additional
24 hours after transfection with fresh medium followed by
the indicated treatment and then prepared for immuno-
blotting, quantitative real-time polymerase chain reaction,
or Sircol collagen assay.
Statistical analysis
Group data are expressed as mean  standard deviation.
Differences between treatment groups were analyzed using
one-way analysis of variance and Duncan post hoc test. A p
value < 0.05 was considered significant.Results
TGF-b1 stimulates Egr-1 protein expression in
normal BMFs
Human BMFs were treated with various concentrations of
TGF-b1. TGF-b1 significantly increased Egr-1 synthesis
(Figure 1). The levels of Egr-1 protein increased approxi-
mately 3.5-fold after stimulation with 2 ng/mL TGF-b1 for
2 hours and declined thereafter.
ERK, JNK, and Smad3 involvement in TGF-b1-
induced Egr-1 signaling
PD98059, SP600125, SB431542, and SIS3 significantly abol-
ished the TGF-b1-induced levels of Egr-1, but not SB203580
(Figure 2A). We further knocked down Smad3 using Smad2/
3 siRNA and found that TGF-b1-induced Egr-1 was
completely abrogated (Figure 2B).
Egr-1 mediating TGF-b1-induced fibrotic gene
expression and collagen production
We explored the effect of knocking down Egr-1 on the
transcript expression levels of COL1A1 and COL1A2 genes
using quantitative real-time polymerase chain reaction in
BMFs. As shown in Figures 3A and 3B, COL1A1 and COL1A2
Figure 2 ERK, JNK, and Smad3 were involved in the TGF-b1-induced Egr-1 in BMFs. (A) BMFs were pretreated with 10mM ERK
inhibitor PD98059, 10mM JNK inhibitor SP600125, 10 mM p38 mitogen-activated protein kinase inhibitor SB203580, 10mM activin
receptor-like kinase 5 inhibitor SB431542, or 10mM Smad3 inhibitor SIS3 for 1 hour before exposure to 2 ng/mL TGF-b1 for 2 hours.
(B) BMFs were transfected with 60nM Smad2/3 small interfering RNA for 24 hours and then incubated with 2 ng/mL TGF-b1 for
2 hours. Egr-1 protein levels in (A) and (B) were measured by western blot analysis. Experiments were repeated three times with
BMF Strain 1 for statistical analyses and were verified once with each of the other 2 strains. All the experimental results were
similar. A representative result is shown. Results were further quantified by densitometric analysis, normalized by the level of b-
actin, and expressed as the fold change relative to the untreated controls as shown in the lower panels of (A) and (B). * p < 0.05
compared with the control. ** p < 0.05 compared with 2 ng/mL TGF-b1. BMF Z buccal mucosal fibroblast; Egr Z early growth
response; ERK Z extracellular signal-regulated kinase; JNK Z c-Jun N-terminal kinase; TGF Z transforming growth factor.
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alone. Knocking down Egr-1 with Egr-1 siRNA completely
inhibited the levels of TGF-b1-induced COL1A1 and COL1A2
mRNAs. The total amount of TGF-b1-induced collagen
accumulation also significantly decreased in BMFs trans-
fected with Egr-1 siRNA as assessed by the Sircol assay
(Figure 3C).
EGCG inhibiting TGF-b1-stimulated Egr-1 and
collagen production
We investigated the effects of lovastatin, curcumin, or
EGCG on TGF-b1-induced Egr-1 protein expression in BMFs.
Results showed that 20mM lovastatin, 10mM curcumin, and
10mM EGCG inhibited the TGF-b1-induced Egr-1 protein
expression by 69.4%, 64%, and 100%, respectively
(Figure 4A). EGCG inhibited TGF-b1-stimulated Egr-1
expression and collagen production in a dose-dependent
manner (Figures 4B and 4C). At a concentration of 10mM,
EGCG almost completely abrogated the TGF-b1-stimulated
production of collagens (Figure 4C).
Discussion
Many animal models of fibrosis have shown increased Egr-1
expression in affected organs and active Egr-1-dependentsignaling.11 Moreover, several models show improvement
after attenuating the effects of Egr-1. However, contro-
versies concerning the profibrotic function of Egr-1 do
exist. TGF-a-induced lung fibrosis,17 a-naph-
thylisothiocyanate-induced liver fibrosis,18 and carbon-
tetrachloride-induced hepatic fibrosis19 are exacerbated
in Egr-1 null mice. These contrasting results suggest that
the initiating nature of injury, the extracellular stimuli
involved, and the tissue or cell type of its expression could
influence the role of Egr-1 in fibrogenesis. Our previous
study has shown Egr-1 staining in OSF specimen and
elevated Egr-1 induced by arecoline in BMFs.12 In this pre-
sent study, we showed that TGF-b1 induced Egr-1 expres-
sion and that Egr-1 mediated TGF-b1-induced COL1A1 and
COL1A2 mRNA expression and collagen production in BMFs.
Therefore, our results implicate Egr-1 as a key mediator of
TGF-b-regulated fibrosis in the pathogenesis of OSF.
To initiate its cellular action in fibroblasts, TGF-b first
binds to TGF-b receptor II and then recruits and phos-
phorylates TGF-b receptor I (ALK5) to subsequently activate
Smad2/3.20,21 This Smad3 pathway mediates most of the
profibrotic activities of TGF-b.22 In addition to the canoni-
cal Smad pathway, non-Smad signaling is also activated by
the TGF-b receptor complex.23 Furthermore, the ability of
TGF-b to activate MAPKs (ERK1/2, JNK, or p38) has gained
increasing interest. TGF-b-induced MAPK pathways may
activate collagen synthesis independently or in
Figure 3 Egr-1 mediated TGF-b1-induced fibrotic gene expression and collagen production. BMFs were transfected with 60nM
Egr-1 siRNA followed by 2 ng/mL TGF-b1 treatment for 0e48 hours to study the TGF-b1-induced (A) COL1A1 and (B) COL1A2 mRNA
expression using TaqMan Gene Expression Assays. Experiments were repeated three times with BMF Strain 1 for statistical analyses
and were verified once with each of the other two strains. All experimental results were similar. Data are presented as means  SD
(* p < 0.05 compared to control, ** p < 0.05 compared to 2 ng/mL TGF-b1). (C) BMFs were transfected with 60nM Egr-1 siRNA
followed by 2 ng/mL TGF-b1 treatment for 48 hours and then subjected to Sircol collagen assay. Bars represent means  SD of
collagen level, normalized to the level in untreated BMFs, and expressed as fold change relative to untreated controls (* p < 0.05
compared to control, ** p < 0.05 compared to 2 ng/mL TGF-b1). BMF Z buccal mucosal fibroblast; COL1A1 Z type 1 collagen a1
chain; COL1A2Z type 1 collagen a2 chain; EgrZ early growth response; SDZ standard deviation; siRNAZ small interfering RNA;
TGF Z transforming growth factor.
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trix microarrays, Chen et al13 identified Egr-1 as Smad3-
inducible gene in hTERT-BJ1 cells (human foreskin fibro-
blasts). Later, the results from Bhattacharyya et al25 using
ALK5 inhibition in normal primary human dermal fibroblasts
and Smad-deficient mouse primary dermal fibroblastsindicated that TGF-b-stimulated Egr-1 occurred indepen-
dently of ALK5/Smad3 but required ERK1/2 signaling. Our
results showed that SB431542, SIS3, PD98059, and SP600125
attenuated the TGF-b1-induced Egr-1, indicating the
involvement of ALK5/Smad3, ERK, and JNK pathways in
TGF-b1-induced Egr-1 signaling in BMFs. We further showed
Figure 4 EGCG inhibited TGF-b1-induced Egr-1 expression and collagen production. (A) BMFs were pretreated with 20mM lova-
statin, 10mM curcumin, or 10mM EGCG, for 1 hour before exposure to 2 ng/mL TGF-b1 for 2 hours. (B) BMFs were pretreated with
increasing concentrations of EGCG (0e10mM) for 1 hour, and then with 2 ng/mL TGF-b1 for 2 hours. Egr-1 protein levels in (A) and
(B) were measured by western blot analysis. Experiments were repeated three times with BMF Strain 1 for statistical analyses and
were verified once with each of the other two strains. All experimental results were similar. A representative result is shown.
Results were further quantified by densitometric analysis, normalized by the level of b-actin, and expressed as the fold-change
relative to the untreated controls as shown in the lower panels of (A) and (B) (* p < 0.05 compared with the control, **
p < 0.05 compared with 2 ng/mL TGF-b1). (C) BMFs were pretreated with increasing concentrations of EGCG (0e10mM) for 1 hour,
and then incubated with 2 ng/mL TGF-b1 in the presence or absence of EGCG for 48 hours. Collagen from BMFs was quantified with
Sircol collagen assay. Bars represent means  standard deviation of collagen level, normalized to the level in untreated BMFs, and
expressed as fold change relative to untreated controls (* p < 0.05 compared to control, ** p < 0.05 compared to 2 ng/mL TGF-b1).
BMF Z buccal mucosal fibroblast; EGCG Z epigallocatechin-3-gallate; Egr Z early growth response; TGF Z transforming growth
factor.
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abolished TGF-b1-induced Egr-1. These results confirm that
in BMFs, upregulation of Egr-1 by TGF-b depends on ALK5/
Smad3 signaling. Our results suggest the different signaling
between dermal and buccal fibroblasts.
To date, no known treatment for OSF is effective in
reversing the disease. Considering the role of Egr-1 in the
pathogenesis of OSF, blocking Egr-1 may be a novel strategy
to control pathological fibrogenesis in OSF. Although there
are no specific inhibitors of Egr-1, multiple pharmacological
agents such as statins, curcumin, and EGCG have shown
potent effects of Egr-1 inhibition.11,13,26,27 All these threeagents modulate cellular signaling to exert anti-
inflammatory, antioxidative, and chemopreventive ef-
fects.28,29 In addition, they suppress fibrotic diseases in
various animal models. Our previous studies have demon-
strated these agents may be capable of blocking fibrogenic
signaling in oral tissues.30e32 Therefore, we examined the
effects of these agents on the expression of Egr-1 in BMFs.
Our results revealed that lovastatin, curcumin, and EGCG
all significantly inhibited the TGF-b1-induced Egr-1 protein
expression. EGCG (10mM) completely inhibited TGF-b1-
stimulated Egr-1 and abrogated TGF-b1-stimulated
collagen production. Our previous study has shown that
EGCG suppress Egr-1-mediated TGFb-induced collagen 113EGCG completely blocks the arecoline-induced Egr-1 and
collagen gel contraction in BMFs.12 We have also shown that
EGCG fully blocks the TGF-b1-induced connective tissue
growth factor (CCN2/CTGF) in BMFs.31 Taken together,
EGCG, with its history of safe consumption in green tea,
may be useful as prevention or therapy for OSF.
In conclusion, this study demonstrates that TGF-b1
stimulates Egr-1 production in BMFs. ALK5/Smad3, ERK1/2,
and JNK pathways mediate TGF-b1-induced Egr-1 in BMFs.
Egr-1 subsequently induces COL1A1 and COL1A2 mRNAs
expression and collagen production in BMFs. EGCG blocks
the ability of TGF-b1 to produce collagen by attenuating
the TGF-b1-induced Egr-1 activation in BMFs. EGCG
potentially serves as a novel agent for prevention or
treatment of OSF.
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